Article of the Month:
The FARES-II Multicenter RCT (Canada and the US) published this month in JAMA:
538 patients of which 420 underwent analysis. 207 entered the FFP group (3u FFP if <60kg, 4u FFP if > 60kg) and 213 entered the PCC group. PCC showed improvements in:
- “Haemostatic effectiveness”,
- Blood product administration (6.6units with PCC vs 9.3 units with FFP)
- Adverse events (36% vs 47%)
- AKI (10% vs 18%)
Importantly this trail used higher doses of PCC (24u/kg) than previous studies, perhaps explaining some of the benefits seen (which were not identified in similar, albeit smaller trials previously) Incidence of thrombotic events was not increased with PCC vs FFP.
Previous Articles of the Month
